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Introduction
Continuous renal replacement therapy (CRRT) in the
ICU is a common treatment in acute renal failure (ARF).
CRRT is mainly conceived as merely supportive and as a
replacement of the lost kidney function. On the other
hand, evidence accumulating over the last years demon-
strates that many soluble mediators of the systemic in-
flammatory (and anti-inflammatory) response syndrome
can be removed by CRRT. This has led to the suggestion
that CRRT could play a major role in sepsis therapy as
immunomodulatory treatment and not only as a blood
purification technique. In this perspective, whereas ani-
mals studies yielded encouraging results, early clinical
trials only showed minor clinical benefits, mainly dealing
with hemodynamic improvements. The question of treat-
ment dose has appropriately been raised which still has to
be defined and it represents a matter of controversy. A
large-scale clinical trial has clarified issues on treatment
dose in ARF, but a sufficiently powered study on hemofil-
tration dose in sepsis is still lacking.
In this article we will review the rationale for applica-
tion of CRRT in treatment of the septic syndrome with
specific focus on the use of high ultrafiltration rates (i.e.
high-volume hemofiltration: HVHF). We will integrate
the discussion into the most recent hypothesis proposed
to explain some of the clinical results obtained with high
efficiency non-selective removal of mediators of sepsis.
Further, we will describe the necessary technical require-
ments for HVHF and the most recent machine develop-
ment concurring with these.
The Rationale of CRRT in Sepsis
The sepsis syndrome has been described as a systemic
malignant inflammation, where the circulation is invaded
by enormous amounts of pro-inflammatory mediators
produced by activated mononuclear cells. In fact, sepsis is
associated with an overwhelming, systemic overflow of
both pro- and anti-inflammatory mediators; this leads to
altered immune cellular responsiveness, generalized en-
dothelial damage and multiple organ failure derived from
a complete disruption of the ‘immunological homeostasis’
[1, 2].
The characteristics of the mediator network are of fun-
damental relevance in order to allow selection of the most
rational and effective treatment approach. The network is
redundant and synergistic; it acts like a cascade modu-
lated by multiple positive and negative feedback loops. A
vast array of humoral mediators involved have been iden-
tified exerting pro-inflammatory effects; on the other
hand, a seemingly equally broad spectrum of molecules
with opposite function has been demonstrated to emerge
in the time course of the septic syndrome. Both pro- and
anti-inflammatory mediators, while designed to mainly
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Fig. 1. The sequential appearance of various cytokines in sepsis.
act in an autocrine and/or paracrine mode, are spilling
over into the circulation during sepsis and display disas-
trous systemic effects. In some circumstances, depending
on which additional stimuli are present, the same media-
tor can exert alternatively pro- or anti-inflammatory ac-
tion. Apart from inciting substances (e.g. endotoxin, prod-
ucts of cell injury) and very early mediators of the septic
process (e.g. complement factors, F XIIa) chemokines and
cytokines have a central role in the propagation of the
inflammatory process including regulatory effects on im-
mune cells. In fact, mortality in sepsis is correlated with
persistently elevated levels of pro-inflammatory cytokines
[3, 4] and in a parallel way, persisting immune cellular
hypo-responsiveness associated with high levels of anti-
inflammatory cytokines [5, 6]. This has been similarly
observed early in the sequence of effects induced by endo-
toxin injection in animal models (fig. 1) [7].
The Peak Concentration Hypothesis
The concept of blocking one mediator has not led to
measurable outcome improvement in patients with sepsis
[8]. Possibly more rigidly defined subgroups would gain
profit by TNF-antagonizing treatments [9]. On the other
hand, it has been shown that antagonizing a cytokine
could lead to deleterious consequences encompassing sub-
stantially higher mortality [10]. A low-level TNF response
seems to be necessary for the host defense to infection [11,
12] as well as high levels seemingly need to be modulated
by an anti-inflammatory feedback; in sepsis, however,
failed regulation may cause an excess of anti-inflammato-
Fig. 2. The peak concentration hypothesis: the sequential appear-
ance of various cytokines in sepsis is schematically depicted. By
CRRT, peak plasma cytokine levels could be unselectively reduced
bringing the organism at a less severe degree of immunological
derangement. Lower levels of pro- and anti-inflammatory mediators
could allow the restoration of immuno-homeostasis.
ry response which generates monocyte downregulation and
exposes to further infections. Both these processes (inflam-
mation and anti-inflammation) are designed to act in
response to specific stimuli in a well-balanced fashion
defined as immuno-homeostasis. The excess of one over
the other may produce a deleterious effect either leading to
systemic inflammation or immune-cell hyporesponsive-
ness. In the septic syndrome, it seems that these processes
are both exaggerated in the time course of the disease and
may put the patient alternatively at risk for endothelial
dysfunction and shock, or overwhelming infections.
Furthermore, the time point in the septic process of
therapeutic intervention seems to be crucial. As the net-
work acts like a cascade early intervention would seem
most beneficial. On the other hand, sepsis does not fit a
one-hit model but shows complex and varying time courses
in mediator levels. Neither single-mediator-directed nor
one-time interventions therefore seem appropriate.
One of the major criticisms attributed to continuous
blood purification treatments in sepsis – its lack of speci-
ficity – could turn out to be a major strength. Unspecific
removal of soluble mediators – be they pro- or anti-
inflammatory – without completely eliminating their ef-
fect may be the most logical and adequate approach to a
complex and long-running process like sepsis. The con-
cept of cutting peaks of soluble mediators, e.g. through
continuous hemofiltration (fig. 2), is a paradigm called by
us ‘the peak concentration hypothesis’ [13].
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Ultrafiltration Dose and Outcome
Numerous in vitro as well as animal and human stud-
ies [reviewed in 14] have shown that synthetic filters in
common use in hemofiltration can extract nearly every
substance involved in sepsis to a certain degree. Promi-
nent examples are complement factors [15, 16], TNF,
IL-1, IL-6 [17–19], IL-8 [20] and PAF [21].
Regarding plasma cytokine levels the decreases ap-
peared nevertheless of minor degree. Other studies could
not show any influence on cytokine plasma levels by
CRRT [22, 23].
On the other hand significant clinical benefits in terms
of hemodynamic improvement have been achieved even
without measurable decreases in cytokine plasma levels
[24].
Obviously the removal of substances different to the
measured cytokines was responsible for the achieved
effect. In alternative, bioactive substances including some
of the measured cytokines were removed causing the
observed beneficial effect. When the response to sepsis is
viewed in a network perspective, absolute values would be
less relevant than relative ones within an array of interde-
pendent mediators as even small decreases could induce
major balance changes. This makes measurement of cyto-
kine plasma levels debatable whilst more local or tissue
levels should be measured. These issues are extremely
controversial and do not permit a definitive solution in
favour or against the use of CRRT as a therapy of sepsis.
In this context a further step in clarifying the immunologi-
cal impact of CRRT has been taken by measuring a more
downstream event integrating several cytokine influences:
the monocyte responsiveness [25, 26].
In spite of some encouraging results as mentioned, the
extent of achievable clinical benefit with conventional
CRRT (using conventional filters and flow rates) in sepsis
has generally been disappointing. Consequently it was
sought to improve the efficiency of the methodology
regarding removal of soluble mediators of sepsis by
increasing the amount of plasma water exchange, i.e.
increasing ultrafiltration rates.
Animal studies provided much support of this concept.
Starting in the early nineties several studies using differ-
ent septic animal models examined the effect of high
ultrafiltration rates (up to 300 ml/kg/h) on physiological
parameters and outcome.
In a landmark study, a porcine model of septic shock
induced by endotoxin infusion was investigated [27]. The
animals developed profound arterial hypotension and a
decrease in cardiac output, stroke volume and right ven-
tricular stroke work index. By HVHF at 6 liters/h right
ventricular function, blood pressure and cardiac output
showed a remarkable improvement compared to control
and sham-filtered animals [27, 28]. The same group
extended their findings in the same model by intrave-
nously administering ultrafiltrate of endotoxin-infused
animals into healthy animals. These developed a hemody-
namic picture similar to septic shock whereas animals
infused with ultrafiltrate of healthy animals showed a
moderate blood pressure rise [29].
In a further study by the same group a bowel ischemia-
reperfusion model in pigs was investigated. HVHF
started before clamping of the superior mesenteric artery
significantly diminished bowel damage and prevented
hemodynamic deterioration [30].
These classic studies established that a convection-
based treatment can remove substances with hemody-
namic effects resembling septic shock, when sufficiently
high ultrafiltration rates are applied.
Several studies confirmed and refined these results. In
three of them [31–33] the correlation of survival with
ultrafiltration rate was specifically examined. A direct
correlation could be demonstrated. Significant improve-
ments in cardiac function, systemic and pulmonary vas-
cular resistance and hepatic perfusion [31] were found.
Another study in lambs showed significant improvements
in lung function [34]. Only a minority of studies identified
reduced mediator plasma levels [33, 35].
A very recent study in pigs made septic by induced
pancreatitis compared low-volume CVVH with HVHF of
100 ml/kg/h. In the same study the influence of frequent
filter changes on survival, changes in TNF levels as well as
monocyte and PMNL function was analyzed [33]. Early
filter change allows to delineate the effect of cytokine
removal by adsorption on the filter since membrane
capacity saturates after a few hours. By changing filters,
adsorption is continued to a certain extent.
In this model a hyperdynamic septic picture is induced
through an intervention which approximates underlying
conditions encountered in human sepsis. Additionally the
intervention started late to simulate real clinical condi-
tions. Hemofiltration was commenced when the animals
developed the clinical picture of hyperdynamic septic
shock. HVHF was superior in all mentioned endpoints
and, importantly, increasing ultrafiltration had more ef-
fect than frequency of filter change [33].
Of major influence concerning human sepsis studies
has been the finding that ultrafiltration dose is correlated
to outcome in critically ill patients with ARF. In a large
randomized, controlled study including 425 patients, an
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Fig. 3. Survival rates observed in patients
treated with different hemofiltration dose.
While the effects is evident in the overall
population from group 1 to group 2 and no
further effect is observed on group 3, when
patients are stratified for sepsis, a significant
effect of higher doses of treatment is ob-
served in group 3.
ultrafiltration dose of 35 ml/kg/h increased survival rate
from 41 to 57% compared to a dose of 20 ml/kg/h [36].
Eleven to 14% (per randomization group) of the pa-
tients had sepsis. In these subgroups there was a trend of
direct correlation of treatment dose with survival even
above 35 ml/kg/h in contrast to the whole group where a
survival plateau was reached (fig. 3).
This lends support to the concept of a ‘sepsis dose’ of
hemofiltration in septic patients contrasting to a ‘renal
dose’ in critically ill patients without systemic inflamma-
tion, the former being probably distinctly higher (without
proven upper limit). Of note, there was no increase in
adverse effects even with the highest ultrafiltration dose.
Over the last years several human studies examined
the clinical effects of high-volume hemofiltration. In
20 children undergoing cardiac surgery, zero-balanced
HVHF was administered with UF rates equivalent to 7–
9 liters/h for a 70-kg adult [37]. Endpoints correlating to
the cardiopulmonary-bypass-associated delayed inflam-
matory response were examined. There was a significant
reduction in post-operative blood loss, time to extubation
and improvement in the arterial-alveolar oxygen gra-
dient.
In a prospective cohort analysis in 306 critically ill
patients with varying underlying diseases a mean ultrafil-
tration rate of 3.8 liters/h was applied [38]. Observed sur-
vival rates were significantly higher in the treated popula-
tion compared to predicted survival by three well-vali-
dated scores.
A study in 12 critically ill patients with ARF compar-
ing low-volume CVVH (1,500 ml/h) with a high-volume
technique was performed in a non-randomized, compara-
tive fashion [39]. High-flux bicarbonate dialysis amount-
ing to 4,200 ml/h was used and the effect on monocyte
responsiveness (ex vivo endotoxin-stimulated TNF pro-
duction) was studied. Both techniques resulted in early
improvement but only in the high-volume technique dis-
played persistent effects. Ultrafiltrate contained mono-
cyte suppressive activity only with high-flux dialysis.
In another trial in 11 septic patients with shock and
MODS a randomized cross-over design of 6 vs. 1 liters/h
ultrafiltration was applied [40]. The HVHF group dis-
played significantly greater reduction in vasopressor re-
quirements (fig. 4). Both treatment groups showed a de-
crease in C3a and C5a plasma levels which was signifi-
cantly greater in the HVHF group.
Impressive clinical results were obtained in an evalua-
tion of short-term HVHF in 20 patients in catecholamine-
refractory septic shock [41] comprising a patient cohort
with very poor expected survival. A control group was not
defined. Only one 4-hour session of HVHF removing 35
liters of ultrafiltrate replaced by bicarbonate-containing
fluid was applied as soon as mean blood pressure could
not be stabilized above 70 mm Hg with dopamine, nor-
epinephrine and epinephrine after appropriate volume
resuscitation. HVHF was followed by conventional
CVVH. Endpoints were the increase in cardiac index,
mixed venous oxygen saturation and arterial pH and
decrease in epinephrine requirements. Eleven patients
reached all predefined endpoints and showed impressive-
ly good survival (9 of 11) at 28 days. Nine patients did not
reach all endpoints and had a 100% mortality rate. Apart
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Fig. 4. Significant reduction in norepinephrine requirement is ob-
served in unstable septic patients treated with high-volume hemofil-
tration. Less evident is the effect of low-volume CVVH.
from responding to HVHF, only time from ICU admis-
sion to start of HVHF and body weight were survival-
associated factors in the analysis. Patients with higher
body weight did worse possibly because they received a
smaller ultrafiltration dose per body weight as speculated
by the authors.
These trials still need cautious interpretation with
respect to their limited design, but they certainly deliver
sound evidence of feasibility and efficacy to set the stage
for a large-scale trial on HVHF in sepsis.
Unsolved Issues
Ultrafiltration is associated with loss of a vast array of
water-soluble substances. Not all of these losses are de-
sired and many have not been characterized quantitative-
ly [42] or even qualitatively. HVHF constitutes a major
intervention in acid-base balance as much strong ions and
up to now poorly defined small to middle molecular acids
(and bases) of intermediate metabolism are filtered.
Furthermore, lactate replacement fluid leads to hyper-
lactatemia which possibly can be tolerated well even in
septic shock [43], but not in all patient groups [44, 45].
Bicarbonate replacement would appear physiologic but is
very expensive and not available in many parts of the
world.
Losses of hormones, vitamins, molecules of interme-
diate metabolism and amino acids in HVHF have not
been studied up to now. As CRRT can be regarded as a
powerful metabolic intervention (constituting a contin-
uous plasma water exchange), its intensification by using
HVHF may encompass undefined dangers (by loss of spe-
cific substances, by high lactate loads). On the other hand,
it possibly opens a therapeutic avenue to administer sub-
stances with specific metabolic activity without volume
restriction (e.g. inosine [46], pyruvate [47]).
Another issue involved the modification of thermal
energy balance especially when high volume of fluid is
exchanged. Specific studies have not been carried out, but
an increasing consensus exists on the need for a fluid
warmer in the newly designed machines.
Methodological Aspects of HVHF
Major methodological details in using a technique which deserves
a fluid exchange rate of 6 liters/h and more (possibly up to 10 liters/h
what would equal about 140 ml/kg in a 70-kg adult) have to be con-
sidered. To avoid excessive hemoconcentration within the filter with
consecutive clotting problems high blood flows in the range of 400–
500 ml/min have to be applied. For the same reason at least part of
the replacement fluid has to be administered in a predilution mode.
This may reduce middle molecule clearance proportionally by the
dilutional effect at filter entry [55].
Certainly high volumes increase risks of technical problems (cath-
eter problems, disconnection, dosing errors). Catheters have to be
large to tolerate blood flows at least above 300 ml/min. High blood
flows must be maintained at all times and in variable patient posi-
tions with minimal recirculation.
Consequently, the technique needs a high level of supervision by
experienced personnel exclusively devoted to the treated patient.
Most practical in this respect seems to be an intermittent technique
with HVHF over 4–8 h during daytime embedded in conventional
CVVH for the rest of the day. Furthermore, high amounts of replace-
ment fluids are needed which may reach financial limits. Systems
designed for in-line preparation of fluids by cascade filtration may
have to be considered.
Obviously the hemofiltration machine is vital for the safe perfor-
mance of HVHF. First of all machines need to be capable of adminis-
tering volumes in this range including warming capacity. Further
safety regards are appropriate pressure monitoring, exactness in
applying high volumes and calculating balances. Certainly a friendly
user interface and the easiness of use is a must (fig. 5).
The Aquarius Haemofiltration machine (ELS, Germany) has
been developed specifically to reach the above-mentioned goals and
serves as a representative of the latest generation of machines in the
field. In this machine, HVHF can be performed in addition to all
other types of blood purification therapies considered for use in the
ICU.
Blood flows required for effective HVHF in the range of 300–
450 ml/min can be programmed. Ultrafiltration rate in the range of
6 liters/h (requiring replacement fluid infusion rates of about
100 ml/min) can be prescribed as well.
The Aquarius machine delivers pump flow rates up to 450 ml/
min for blood, up to 10 liters/h for pre- or postdilution replacement
and up to 2,000 ml/h for additional fluid removal.
Volume accuracy as well as sensitive, fast-response pressure mon-
itoring is of utmost importance in these high ranges.
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Fig. 5. High-volume hemofiltration performed either in pre or post-
dilution modes (machine: Aquarius from Edwards Life Sciences
GmbH, Unterschleissheim, Germany).
Fig. 6. Coupled plasma filtration with adsorption. Plasma filtered in
a plasma filtration unit is circulated through an adsorbent cartridge
and then returned to the main stream. Reconstituted blood is then
dialyzed (machine: Multimat B from Bellco s.p.a., Mirandola, Italy).
This is properly realized with scales ensuring substitution and fil-
trate volume accuracy with 0.1% precision. Pump accuracy reaches
5%. Only a 50-gram deviation of the target value is permitted before
alarming will be activated. Precision within this range is obligatory
for HVHF.
Replacement fluid can be administered in a pre- and post-dilu-
tion mode and concurrently. Pressure monitoring is installed in the
access and return line as well as in a prefilter position and in the
ultrafiltrate compartment. Sensor accuracy amounts to B5 mm Hg.
The pressure sensors operate without blood-air interface. Air embo-
lism is prevented by an ultrasonic air detector which controls a line
clamp. Effective heating capacity is essential when high volumes are
processed. Otherwise major energy losses and possibly severe hypo-
thermia could be induced in the patient. For this purpose the
machine uses a coil-tubing design which ensures heating up to 39°C
up to 6 liters/h fluid turnover. HVHF is a high-risk procedure regard-
ing immediate consequences of technical or user errors. In order to
minimize their probability of occurrence user-friendly properties are
of high priority. This need is served by the concept of a one-button
machine. A single selector knob guides all functions supported by a
self-explanatory screen.
Other Approaches to High Efficiency Blood
Purification in Sepsis
Cytokines and other immunomodulating substances
have generally molecular weights in the range from 5 to
50 kD. They may be eliminated by diffusion, convection
or adsorption depending on material and the rather vari-
able cut-off of highly permeable membranes (from 30 to
40 kD) [17]. As adsorptive processes easily saturate and
are therefore transient, the effect of CRRT on sepsis could
be limited because of a low convective clearance of many
mediators.
Therefore other approaches to achieve higher mediator
clearance in sepsis have been sought. Apart from increas-
ing ultrafiltration rates, higher removal rates of middle
molecular weight molecules could be achieved by enlarg-
ing pore size of membranes. Animal data [49, 50] as well
as preliminary clinical data [51] demonstrate feasibility
and probable superior removal rates of select cytokines
using larger cut-off membranes.
A study in 30 patients with severe sepsis using contin-
uous plasmafiltration for 34 h [52] found attenuation of
the acute-phase response and a trend towards clinical ben-
efit although not significant (fewer failing organs). A fur-
ther refining has been achieved with plasma filtration
coupled with adsorption and followed by dialysis or filtra-
tion (fig. 6) [53]. This would allow effective removal of
mediators in the borderline zone of filtration by hemofil-
ters (40–60 kD) without the need of exogenous plasma
replacement. Furthermore higher plasma clearance rates
could be achieved. An animal study [54] and a first clini-
cal trial reported beneficial effects on hemodynamic and
immune cell function [26, 55].
Conclusions on efficiency would be premature to draw.
Taken the available data together more studies are re-
quired to see a major advantage in laboratory and clinical
endpoints with plasma filtration compared to ultrafiltra-
tion techniques.
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Certainly larger pore size membranes and plasma fil-
tration combined with sorbent techniques enlarge the
therapeutic armamentarium significantly. They consti-
tute a promising adjunctive modality easily to be used in
combination with hemofiltration.
Concluding Remarks
A vast array of mostly water-soluble mediators play a
strategic role in the septic syndrome. Compared to elimi-
nating or completely antagonizing single mediators, ther-
apeutic intervention by nonselective removal of pro- and
anti-inflammatory mediators seems a rational and possi-
bly superior concept. A further advantage seems to be
constituted by a continuously acting therapy as in the case
of continuous renal replacement therapies. Hereby, se-
quentially appearing peaks of systemic mediator overflow
could be curbed as well as persistently high plasma levels
reduced. This process is proposed as the underlying bio-
logical rationale for a series of innovative therapies in sep-
sis. The whole story of antagonizing pro- and anti-inflam-
matory processes by reducing the relative excess of active
substances undergoes the term of ‘peak concentration
hypothesis’.
Recent animal and human trials have delivered much
support to this concept. It has been conclusively shown
that treatment dose in CRRT is a major factor concerning
survival in ARF in the critically ill patient. There is accu-
mulating evidence of increased efficacy of high-volume
hemofiltration compared to conventional CVVH in terms
of laboratory and clinical improvement including surviv-
al. Machines to perform HVHF safely are available on the
market.
Yet the evidence still is not strong enough to recom-
mend HVHF outside clinical studies taking into account
possible adverse effects of the technique. A large-scale
clinical trial is urgently needed to resolve the issue.
Other blood purification techniques using large pore
membranes or plasma filtration with sorbent perfusion
are in the early stages of clinical testing. They are concep-
tually promising and possibly constitute an important
refinement.
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